<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169350</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01442</org_study_id>
    <secondary_id>NCI-2011-01442</secondary_id>
    <secondary_id>8468</secondary_id>
    <secondary_id>CDR0000665359</secondary_id>
    <secondary_id>UW-8468</secondary_id>
    <secondary_id>6971</secondary_id>
    <secondary_id>8468</secondary_id>
    <secondary_id>N01CM37008-9-0-0</secondary_id>
    <nct_id>NCT01169350</nct_id>
  </id_info>
  <brief_title>18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma</brief_title>
  <official_title>A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying 18F-fluoromisonidazole and fludeoxyglucose F 18 PET/CT scans&#xD;
      to see how well they work in assessing oxygen in tumor tissue of patients with soft tissue&#xD;
      sarcoma undergoing chemotherapy with or without radiation therapy. Using diagnostic&#xD;
      procedures, such as 18F-fluoromisonidazole and fludeoxyglucose F 18 PET scan and CT scan, to&#xD;
      find oxygen in tumor cells may help in planning cancer treatment. It may also help doctors&#xD;
      predict how well a patient will respond to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the potential of 18F-fluoromisonidazole ([18F] FMISO) as a non-invasive indicator&#xD;
      of tissue hypoxia to provide tumor-imaging data that correlates with tissue markers of&#xD;
      hypoxia in patients with soft tissue sarcoma treated with neoadjuvant chemotherapy with or&#xD;
      without radiotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Test [18F] FMISO tumor uptake as an independent predictor of patient outcome and if it&#xD;
      provides additional predictive power over fludeoxyglucose F 18 PET scan.&#xD;
&#xD;
      II. Test [18F] FMISO tumor uptake as a predictor of response in the subgroup of patients&#xD;
      treated with radiotherapy and chemotherapy.&#xD;
&#xD;
      III. Test the reproducibility of [18F] FMISO uptake in tumors by imaging the same patients on&#xD;
      sequential days in a test-retest protocol.&#xD;
&#xD;
      IV. Determine the relationship between hypoxia-related biomarkers (HIF1-a and VEGF),&#xD;
      proliferation biomarkers (microvascular density, p53, and Ki-67), and regional [18F] FMISO&#xD;
      uptake in tumor.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo fludeoxyglucose F 18 [18F] FDG and 18F-fluoromisonidazole ([18F] FMISO)&#xD;
      positron emission tomography (PET)/CT scans before starting neoadjuvant chemotherapy (without&#xD;
      or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
&#xD;
      NOTE: Some patients may undergo repeat [18F] FMISO PET/CT scan within 48 hours after the&#xD;
      first [18F] FMISO scan to evaluate the variability (test-retest) of this imaging measurement.&#xD;
&#xD;
      Blood samples are collected after completion of [18F] FMISO and [18F] FDG PET/CT scans for&#xD;
      laboratory biomarker studies by IHC assays. Tumor samples from biopsy or surgery are also&#xD;
      collected for biomarker studies.&#xD;
&#xD;
      After completion of study procedures, patients are followed up periodically for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding source ended earlier than anticipated&#xD;
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline Hypoxic Volume (HV)</measure>
    <time_frame>Baseline and up to 2 years</time_frame>
    <description>ANOVA and Kruskal-Wallis analysis will be performed across the different categories to look for significant associations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Multivariate Cox regression will be used. The outcome is binary and generalized linear models and logistic regression will be employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>From start of treatment to the follow-up review where recurrent disease is first detected, assessed up to 2 years</time_frame>
    <description>Multivariate Cox regression will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Radiation Therapy (XRT) by RECIST Criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be approached using multivariate logistic regression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <condition>Stage I Adult Soft Tissue Sarcoma</condition>
  <condition>Stage II Adult Soft Tissue Sarcoma</condition>
  <condition>Stage III Adult Soft Tissue Sarcoma</condition>
  <condition>Stage IV Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F FDG and 18F FMISO PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Undergo 18F FDG and 18F FMISO PET/CT scans</description>
    <arm_group_label>Diagnostic (18F FDG and 18F FMISO PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-fluoromisonidazole</intervention_name>
    <description>Undergo 18F FDG and 18F FMISO PET/CT scans</description>
    <arm_group_label>Diagnostic (18F FDG and 18F FMISO PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo 18F FDG and 18F FMISO PET/CT scans</description>
    <arm_group_label>Diagnostic (18F FDG and 18F FMISO PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo 18F FDG and 18F FMISO PET/CT scans</description>
    <arm_group_label>Diagnostic (18F FDG and 18F FMISO PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (18F FDG and 18F FMISO PET/CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed intermediate- or high-grade soft tissue sarcoma&#xD;
&#xD;
               -  Biopsy proven or highly suspicious primary or recurrent disease&#xD;
&#xD;
               -  Tumor size ≥ 2 cm&#xD;
&#xD;
          -  Scheduled to undergo neoadjuvant chemotherapy with or without radiotherapy&#xD;
&#xD;
          -  Life expectancy ≥ 12 months&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Willing to undergo PET scanning&#xD;
&#xD;
          -  Willing to undergo possible urinary bladder catheterization (for patients with pelvic&#xD;
             or proximal thigh tumors)&#xD;
&#xD;
          -  Able to lie on the imaging table for up to 1.5 hours&#xD;
&#xD;
          -  Weight ≤ 400 lbs&#xD;
&#xD;
          -  Not pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Eary</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
          <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Received Baseline FDG PET and FMISO PET</population>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
          <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="45" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline Hypoxic Volume (HV)</title>
        <description>ANOVA and Kruskal-Wallis analysis will be performed across the different categories to look for significant associations.</description>
        <time_frame>Baseline and up to 2 years</time_frame>
        <population>Study ended with 8 patients imaged at baseline and only 3 patients had 18F FMISO following therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
            <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline Hypoxic Volume (HV)</title>
          <description>ANOVA and Kruskal-Wallis analysis will be performed across the different categories to look for significant associations.</description>
          <population>Study ended with 8 patients imaged at baseline and only 3 patients had 18F FMISO following therapy.</population>
          <units>Cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Multivariate Cox regression will be used. The outcome is binary and generalized linear models and logistic regression will be employed.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Study ended. No patients were assessed for overall survival.No data were collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
            <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Multivariate Cox regression will be used. The outcome is binary and generalized linear models and logistic regression will be employed.</description>
          <population>Study ended. No patients were assessed for overall survival.No data were collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>Multivariate Cox regression will be used.</description>
        <time_frame>From start of treatment to the follow-up review where recurrent disease is first detected, assessed up to 2 years</time_frame>
        <population>Study ended. No patients were assessed for disease free survival.No data were collected for this assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
            <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <description>Multivariate Cox regression will be used.</description>
          <population>Study ended. No patients were assessed for disease free survival.No data were collected for this assessment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Radiation Therapy (XRT) by RECIST Criteria</title>
        <description>Will be approached using multivariate logistic regression.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Study ended. No patients were assessed for response to radiation therapy (XRT) by RECIST criteria. No data were collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
            <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Radiation Therapy (XRT) by RECIST Criteria</title>
          <description>Will be approached using multivariate logistic regression.</description>
          <population>Study ended. No patients were assessed for response to radiation therapy (XRT) by RECIST criteria. No data were collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected 24hr +/- 4 hours after each administration of [18F] FMISO.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (18F FDG and 18F FMISO PET/CT)</title>
          <description>Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.&#xD;
fludeoxyglucose F 18: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
18F-fluoromisonidazole: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
positron emission tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
computed tomography: Undergo 18F FDG and 18F FMISO PET/CT scans&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Janet F. Eary</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-598-6244</phone>
      <email>jeary@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

